BioLab Holdings
BioLab Holdings is a Mesa, Arizona-based medical manufacturer that develops and distributes advanced wound care products — amnion membrane allografts, synthetic antimicrobial matrices, and bioengineered dressings — serving healthcare providers, wound care centers, and national distribution partners across the U.S.
- Company typePrivate
- Founded2023
- HeadquartersMesa, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioLab Holdings does
BioLab Holdings, Inc. is a Mesa, Arizona-based privately held medical manufacturer specializing in advanced wound care and regenerative medicine solutions. The company develops, manufactures, and distributes a portfolio of tissue allografts and synthetic wound care products — including the Membrane Wrap™ amnion-based product line (single-, dual-, and triple-layer variants plus ocular and hydrated formats), the Microlyte® SAM fully synthetic antimicrobial matrix, Microlyte® PainGuard™ with lidocaine delivery, and the Mānuka honey-based APIS® line distributed under partnership with SweetBio. The technology stack extends into adjacent modalities through investments in cold atmospheric plasma (plasmapax® via terraplasma medical) and fish collagen biomaterials (Real Collagen GmbH), with multiple active clinical trials (CAMP RWE, BIOCAMP, CAMPR-II, BIO-SEE) generating evidence for chronic wound indications including diabetic foot ulcers and venous leg ulcers.
BioLab operates through two wholly owned subsidiaries — BLS Labs, LLC (tissue banking: donor screening, recovery, processing, storage, distribution) and BLS Sales & Marketing, LLC — both holding AATB Level A accreditation. Revenue is generated through one-time sales of medical devices and biologics to healthcare providers, wound care centers, and a national distribution network of channel partners, augmented by a Product Reimbursement Team that achieves a 96% approval rate at second-level payer appeals. Pricing is quote-based and not publicly disclosed.
The leadership team combines deep medical device and biologics experience, with the CEO and Chairman co-founding the company after a career pivot from telecommunications. Strategic direction emphasizes inorganic portfolio expansion (four partnerships/investments within roughly a year), clinical evidence generation, operational scaling (37 hires in the past year), and geographic breadth including initial Canada registration alongside U.S. operations across multiple state licenses.
BioLab Holdings firmographics
Firmographics- Name
- BioLab Holdings
- Legal name
- BioLab Holdings, Inc.
- Website
- https://biolabholdings.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BioLab Holdings is a Mesa, Arizona-based medical manufacturer that develops and distributes advanced wound care products — amnion membrane allografts, synthetic antimicrobial matrices, and bioengineered dressings — serving healthcare providers, wound care centers, and national distribution partners across the U.S.
- Ownership category
- akta.pro rank
BioLab Holdings industry classification
Industry- Product category
- Wound Care Medical Devices
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)
Keywords
Where BioLab Holdings is headquartered
LocationHeadquarters
- HQ city
- Mesa
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioLab Holdings business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Medical Device and Tissue Product Sales: Sale of wound care medical devices and biologics including membrane products, synthetic antimicrobial matrices, and related wound care solutions to healthcare providers and patients through distribution network.
- Reimbursement Support Services: Providing reimbursement and insurance verification services to support providers with claims resolution and payer negotiations, with 96% approval rate at second-level appeal stage.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
BioLab Holdings product offering
Product offeringCore offering
BioLab Holdings is a Phoenix-based medical manufacturer that develops, produces, and distributes advanced wound care products including amnion-based membrane allografts (Membrane Wrap line), synthetic antimicrobial matrices (Microlyte® SAM™ and PainGuard™), and APIS® bioengineered wound dressings, supported by a national distribution network and dedicated reimbursement support services for healthcare providers treating chronic wounds.
Differentiator
Problem solved
Functional benefit
Brands
- RealRecovery: A cosmetic companion product addressing patient needs.
- Microlyte SAM
- Microlyte PainGuard
- APIS
- Membrane Wrap
- Membrane Wrap Lite
- Tri-Membrane Wrap
- Membrane Wrap Hydro
- Membrane Wrap Amniotic Hydro
- Membrane Lite Restore Ocular
Products and services
- Membrane Wrap™ Product Line (Amnion-based Tissue Allografts) Minimally manipulated amnion-amnion human tissue allografts used as protective barriers and coverings for chronic and acute wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and ocular surface protection. All variants are donor-screened, tested for infectious diseases, and terminally sterilized; processed under AATB Level A accreditation.
- Microlyte® SAM™ Synthetic Antimicrobial Matrix Fully synthetic, ultra-thin porous matrix made of bioresorbable polymers designed to mimic human ECM, containing ionic and metallic silver at low, non-toxic levels providing 99.99% reduction in microbial burden. Conforms to wound-bed micro-crevices and maintains a moist healing environment for chronic wound care.
- Microlyte® PainGuard™ (Synthetic Antimicrobial Matrix with Lidocaine) Synthetic antimicrobial matrix with ionic and metallic silver providing 99.99% microbial reduction, combined with uniform unit-dose lidocaine HCl release for simultaneous pain relief. Over 80% of lidocaine is released within the first 30 minutes, providing antimicrobial action plus localized pain management for wound care patients.
- APIS® Bioengineered Wound Care Bioengineered wound care solution combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite for chronic and acute wounds. Distributed by BioLab Holdings for hospitals, wound care centers, and physician offices nationwide; products are FDA-cleared and Medicare-covered.
- plasmapax® Cold Atmospheric Plasma Device Portable cold atmospheric plasma (CAP) device for antimicrobial treatment in wound care, dermatology, and podiatry settings. The device has been used in over 100,000 treatments globally prior to its U.S. commercial expansion via BioLab Holdings' partnership with terraplasma medical, with FDA clearance as the goal for U.S. market entry.
Quantifiable outcome
- 96% approval rate at second-level appeal stage for reimbursement claims
- +3 more outcomes
Companies that use BioLab Holdings
Customer profileSegments3 records
Ideal customer profiles2 records
BioLab Holdings technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BioLab Holdings partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and strategic.
- SweetBio, Inc.coreStrategic distribution partnership to expand access to SweetBio's APIS® bioengineered wound care products through BioLab's national distribution network. APIS® is the first and only wound care solution combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. Products are already Medicare-covered and FDA-cleared, strengthening BioLab's continuum-of-care portfolio.
- terraplasma medical GmbHcoreInvestment and partnership to commercialize plasmapax®, a portable cold atmospheric plasma (CAP) device for antimicrobial treatment in wound care, dermatology, and podiatry. Device has been used in over 100,000 treatments globally and is pursuing FDA clearance. Collaboration aims to expand U.S. market access leveraging BioLab's distribution network.
- Real Collagen GmbHstrategicInvestment and partnership to create new wound care products using fish collagen. This partnership will allow BioLab to develop innovative wound care solutions using alternative collagen sources.
Scale indicators5 records
Recent moves7 records
Expansion highlights8 records
BioLab Holdings competitors and assessment
Company assessmentDirect peers
- Organogenesis Holdings: Public regenerative medicine company (NASDAQ: ORGO) selling amniotic membrane products (e.g., Apligraf, Dermagraft, PuraPly) directly competitive with BioLab's Membrane Wrap and Microlyte lines in chronic wound care.
- MiMedx Group: Pioneer in dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for diabetic foot ulcers, venous leg ulcers, and surgical wounds, competing head-to-head with BioLab's Membrane Wrap portfolio.
- Integra LifeSciences: Public medical device company with a sizable regenerative tissue and wound care franchise (Integra Dermal Regeneration Template, AmnioExcel), overlapping BioLab's amnion-based skin substitute category.
- MTF Biologics: Non-profit tissue bank and biologics manufacturer supplying amniotic membranes and skin allografts with AATB accreditation comparable to BioLab's BLS Labs subsidiary in tissue-recovery operations.
- Vivex Biologics: Emerging regenerative medicine company selling amniotic and umbilical tissue products (AmnioFix, Cyma) overlapping BioLab's Membrane Wrap positioning in chronic and surgical wound care.
Broad incumbents
- Smith & Nephew: Global medical device incumbent with large Advanced Wound Management and Skin Bioactive franchises competing with BioLab on antimicrobial dressings, biologics, and chronic wound solutions.
- ConvaTec: Global wound care and ostomy specialist with hydrocolloids, antimicrobial dressings, and biologic skin substitutes that compete broadly in the chronic-wound market BioLab serves.
- Coloplast: European medical products incumbent with a dedicated wound & skin care business (Biatain, Convatec-comparable portfolios) addressing the same hospital and home-care chronic wound segments as BioLab.
- 3M Health Care (formerly Acelity/KCI): Owns the KCI negative pressure wound therapy and advanced wound care lines (V.A.C., Snap, Promogran) commonly combined with skin substitutes like BioLab's membrane products in chronic-wound pathways.
- Mölnlycke Health Care: Global wound care and surgical solutions company (Mepilex, Mepitel) competing with BioLab's antimicrobial and protective dressings in both hospital and outpatient chronic-wound channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioLab Holdings social profiles
Digital presenceBioLab Holdings financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioLab Holdings leadership team
Management profileNumber of profiles
Profiles12 records
BioLab Holdings subsidiaries and ownership
Company hierarchySubsidiaries2 records
BioLab Holdings funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioLab Holdings M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioLab Holdings
What does BioLab Holdings do?
BioLab Holdings is a Phoenix-based medical manufacturer that develops, produces, and distributes advanced wound care products including amnion-based membrane allografts (Membrane Wrap line), synthetic antimicrobial matrices (Microlyte® SAM™ and PainGuard™), and APIS® bioengineered wound dressings, supported by a national distribution network and dedicated reimbursement support services for healthcare providers treating chronic wounds.
Is BioLab Holdings a public or private company?
BioLab Holdings is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioLab Holdings founded?
BioLab Holdings was founded in 2023. It employs 101 to 250 people.
Where is BioLab Holdings based?
BioLab Holdings is headquartered in Mesa, United States, in the North America region.
How does BioLab Holdings make money?
Two revenue lines are on record. Medical Device and Tissue Product Sales are the primary driver. The others are reimbursement Support Services.
Who are BioLab Holdings's main competitors?
Direct peers on record are Organogenesis Holdings, MiMedx Group, Integra LifeSciences, MTF Biologics and Vivex Biologics. Broad incumbents are Smith & Nephew, ConvaTec, Coloplast, 3M Health Care (formerly Acelity/KCI) and Mölnlycke Health Care.
Does BioLab Holdings have an API?
No public API is recorded for BioLab Holdings.
What industry is BioLab Holdings in?
BioLab Holdings's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 2836.